Margherita Rimini

20PUBLICATIONS
72CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyPredictive and prognostic markersHaematological tumoursCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Aug 12, 2026
Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting.

|Jul 29, 2026
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab.

|Apr 17, 2026
Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group).

|Nov 12, 2025
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.

Margherita Rimini, Lorenzo Fornaro, Masafumi Ikeda

|Aug 26, 2025
Ivosidenib for IDH1-Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real-World Study.

Monica Niger, Margherita Rimini, Florian Castet

|Jul 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.

Federica Lo Prinzi, Francesca Salani, Silvia Camera

Pageof 4

Frequent Collaborators

8 joint publications

Andrea Casadei-Gardini

6 joint publications

Monica Niger

5 joint publications

Mara Persano

4 joint publications

Caterina Vivaldi